EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Trial Profile

EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-II
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 24 Mar 2016 According to Boston Scientific media release, results will be published at the American College of Cardiology's 65th Annual Scientific Session.
    • 19 May 2015 According to Boston Scientific Corporation media release, results (n=466, diabetic patients) were presented at the Swiss Cardiovascular Center in Bern, Switzerland.
    • 19 May 2015 Results from substudy (n=466, diabetic patients) and EVOLVE II trial published in the Boston Scientific Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top